- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05551598
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
September 20, 2022 updated by: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a multicenter, randomized, double-blind, placebo-controlled Phase Ⅱ study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with neuromyelitis optica spectrum disorder (NMOSD).
Participants will be randomly enrolled into three groups: Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group, and Placebo group.
The primary outcome measure is time to first protocol-defined relapse.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiaqi Liu
- Phone Number: +86-15600050094
- Email: liujiaqi01@mail.ecspc.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-60 years (inclusive) at the time of signing the informed consent form, both men and women;
- Participants meet the 2015 international consensus diagnostic criteria for neuromyelitis optica spectrum disease (NMOSD) and are AQP4-IgG positive or negative (acceptable test results within 24 weeks before signing the informed consent form);
- Experienced at least 2 attacks within 1 year before screening and/or at least 3 relapses in the past 24 months, but have at least 1 documented clinical evidence of attack or relapse (including the first attack) within 12 months before screening;
- Expanded disability status scale (EDSS) ≤ 7.5 points at screening and baseline retest;
- Participants voluntarily sign the informed consent form and voluntarily complete the trial according to the protocol requirements.
Exclusion Criteria:
- Pregnant or lactating female participants, or participants planning to have a child during the study;
- Any surgical procedure within 4 weeks before randomization, with evidence of other demyelinating diseases or progressive multifocal leukoencephalopathy (PML);
- Known active infection (excluding nail bed fungal infection or dental caries) within 4 weeks before randomization;
- Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV antibody) is positive;
- History of drug or alcohol abuse or mental disorder within 1 year before randomization;
- Evidence of active tuberculosis (TB; excluding patients receiving drugs to prevent latent TB infection);
- Evidence of active interstitial lung disease;
- Receipt of any live or live attenuated vaccine within 6 weeks before randomization;
- History of malignancy, including solid tumors, hematological malignancies, and carcinoma in situ (except completely resected and cured basal cell carcinoma and squamous cell carcinoma or cervical carcinoma in situ) within the past 5 years;
- History of severe drug allergy, allergy or intolerance to Mitoxantrone and liposomes (shock, allergic reactions);
- Participants with other chronic active immune system diseases other than NMOSD or stable disease but requiring high-dose glucocorticoid maintenance therapy: such as rheumatoid arthritis, scleroderma, Schogren' s syndrome, ulcerative colitis, genetic immunodeficiency or drug-induced immunodeficiency; participants with positive autoantibodies only but without clinical manifestations can be enrolled in the trial;
- Participants with other diseases not suitable for this study as judged by the investigator;
- Received any investigational agent within 3 months prior to randomization, or participated in a medical device clinical study and judged by the investigator to have a potential impact on the results of this trial;
- History of prior NMOSD therapy with any of the following: a. received prior mitoxantrone or anthracycline therapy, total body irradiation, or bone marrow transplantation at any time; b. received rituximab or any experimental B-cell depleting agent within 6 months prior to randomization, unless the participant had a B-cell count higher than LLN in the central laboratory; c. used any of the following within 3 months prior to randomization: Satralizumab,Tocilizumab,inebilizumab,Eculizumab,Alemtuzumab,Ciclosporin,Azathioprine,Cyclophosphamide,Tacrolimus,Mycophenolate mofetil. Any other treatment to prevent relapses in multiple sclerosis (MS) (eg, Interferon, Natalizumab, Glatiramer acetate, Fingolimod, Teriflunomide, or Dimethyl fumarate); d. intravenous immunoglobulin (IVIG) therapy, plasma exchange therapy (PE) within 1 month prior to randomization; e. participants who are receiving oral corticosteroids at doses higher than 30 mg/day in prednisolone conversion; f. anti-CD4, cladribine within 2 years prior to randomization.
- Presence of the following clinically significant diseases: a. cardiac ejection fraction (EF) less than 50% by echocardiography or lower than the lower limit of laboratory values at the study site; history of chronic congestive heart failure, cardiac function NYHA class Ш ~ Ⅳ; b. any of the following events within 3 months before randomization: myocardial infarction, acute coronary syndrome, viral myocarditis, pulmonary embolism, stroke; coronary revascularization within 6 months; c. screening ECG showed QTc interval > 480 ms (according to Fridericia correction formula, QTc = QT/RR^0.33), or a history of severe QTc prolongation.
- Patients with the following abnormalities in laboratory values during screening: a. aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN), alanine aminotransferase (ALT) > 3 × ULN, total bilirubin > 1.5 × ULN (unless due to Gilbert 's syndrome); b. platelet count < 50,000/μL (or < 50 × 10^9/L), hemoglobin < 9 g/dL (or < 90 g/L), white blood cells < 2.0 × 10^3/μL, absolute neutrophil count < 1.0 × 10^3/μL; c. creatinine clearance (CLcr) < 60 mL/min (calculated using the Cockcroft-Gault formula: [140 - age (years)] × [body weight (kg)] × (0.85, if female)/[72 × serum creatinine (mg/dL)]) or receiving dialysis during screening;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group
|
IV, once every 12 weeks (Q12W)
|
EXPERIMENTAL: Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group
|
IV, once every 12 weeks (Q12W)
|
PLACEBO_COMPARATOR: Placebo Injection every 12 weeks (Q12W).
|
IV, once every 12 weeks (Q12W)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to First Protocol-defined Relapse
Time Frame: Up to Week 48
|
Time to First Protocol-defined Relapse was defined as time from randomization to first occurrence of relapse.
Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neuromyelitis optica spectrum disorder (NMOSD).
|
Up to Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
November 15, 2022
Primary Completion (ANTICIPATED)
October 15, 2024
Study Completion (ANTICIPATED)
April 15, 2025
Study Registration Dates
First Submitted
September 20, 2022
First Submitted That Met QC Criteria
September 20, 2022
First Posted (ACTUAL)
September 22, 2022
Study Record Updates
Last Update Posted (ACTUAL)
September 22, 2022
Last Update Submitted That Met QC Criteria
September 20, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Eye Diseases
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Myelitis, Transverse
- Optic Neuritis
- Neuromyelitis Optica
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Mitoxantrone
Other Study ID Numbers
- HE071-CSP-028
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromyelitis Optica Spectrum Disorder
-
Jagannadha R AvasaralaTerminatedMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Neuromyelitis Optica Spectrum Disorder Relapse | Neuromyelitis Optica Spectrum Disorder ProgressionUnited States
-
Feng JinzhouNot yet recruitingNeuromyelitis Optica Spectrum Disorders
-
BiocadRecruitingNeuromyelitis Optica Spectrum DisordersRussian Federation
-
First Affiliated Hospital of Fujian Medical UniversityThird Affiliated Hospital, Sun Yat-Sen University; MyBiotech Co. Ltd, ChinaCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Tianjin Medical University General HospitalCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum DisordersChina
-
Tianjin Medical University General HospitalWithdrawnNeuromyelitis Optica Spectrum Disorder RelapseChina
-
Fu-Dong ShiCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorders | Devic's DiseaseChina
-
MedImmune LLCCompletedNeuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersUnited States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
-
Reistone Biopharma Company LimitedCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityNanfang Hospital of Southern Medical University; Second Affiliated Hospital... and other collaboratorsUnknownNeuromyelitis Optica Spectrum DisordersChina
Clinical Trials on Mitoxantrone Hydrochloride Liposome Injection
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingPeripheral T Cell LymphomaChina
-
Hui ZengCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedAdvanced Gastric CarcinomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingA Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic CancerAdvanced Pancreatic Cancer
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent/Refractory LymphomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownRelapsed or Refractory Peripheral T-cell and NK/T-cell LymphomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedUnresectable or Metastatic Bone and Soft Tissue SarcomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Terminated
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....WithdrawnRelapsing Multiple SclerosisChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina